TENX · Tenax Therapeutics

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.

101 Glen Lennox Drive, Chapel Hill, NC, 27517, United States
Biotechnology
Healthcare

Market Cap

67.39M

52 Wk Range

$1.31 - $19.40

Previous Close

$1.62

Open

$1.62

Volume

1,103,755

Day Range

$1.46 - $1.62

Enterprise Value

-46.56M

Cash

113.7M

Avg Qtr Burn

-12.48M

Insider Ownership

0.15%

Institutional Own.

77.58%

Qtr Updated

Sep 30th 2026